Show simple item record

dc.contributor.authorChamberlin, Hannah C.
dc.contributor.authorAstley, Susan
dc.contributor.authorCowan, Richard A
dc.contributor.authorHague, Christina
dc.contributor.authorHowell, Sacha J
dc.contributor.authorRadford, John A
dc.contributor.authorTenant, Sean
dc.contributor.authorWilliams, Joanna L R
dc.contributor.authorAznar, Marianne Camille
dc.date.accessioned2022-01-11T11:59:32Z
dc.date.available2022-01-11T11:59:32Z
dc.date.issued2021en
dc.identifier.citationChamberlin HC, Astley S, Cowan R, Hague C, Howell SJ, Radford JA, et al. Breast Dose in Young Women Treated for Hodgkin Lymphoma Between 2007 and 2018: A Single Institutional Study. International Journal of Radiation Oncology Biology Physics. 2021;111(3):E304-E5.en
dc.identifier.urihttp://hdl.handle.net/10541/624811
dc.description.abstractBackground Young women receiving supradiaphragmatic radiotherapy for Hodgkin lymphoma (HL) have a greater risk of breast cancer (BC) later in life. However, radiotherapy dose to breast tissue (RDBT) is not routinely nor consistently reported. We hypothesise RDBT has decreased since the implementation of CT-based radiotherapy planning, due to increased awareness of BC risk, and the use of smaller fields and lower doses. We report RDBT in young women treated for HL at a single institution over 11 years. Method All female HL patients treated with supradiaphragmatic radiotherapy from 2007 to 2018 aged ≤ 36y were included and their breast tissue contoured. Tumour doses were 20-36 Gy. Different measures of RDBT were considered, including V4Gy (total breast volume receiving ≥4Gy, cm3), V30Gy, and mean breast dose (MBD, Gy). Correlations between dose measures were assessed using Pearson’s correlation coefficient. Linear relationships between dose measures and time were investigated using chi-square analysis. Results 73 patients were available for analysis. Large variations in RDBT were seen between patients (see table). Results suggest no decrease over time for V4Gy or V30Gy (linear regression coefficients of 8.4 and 0.1; both χ2 >1000). MBD was moderately positively correlated with V4Gy (r = 0.7) and V30Gy (r = 0.5). The size of the tumour (CTV) was found to have weak positive correlation with V4Gy (r = 0.2), MBD (r = 0.4), and V30Gy (r=0.4).Conclusion Despite smaller fields and lower doses, our data gives no evidence of overall RDBT reduction over time, possibly due to a change in radiotherapy referral patterns. The large range of RDBT supports the need to develop individualised BC screening strategies, through initiatives such as the Breast screening After Radiotherapy Dataset (BARD). We recommend V4Gy, V30Gy and MBD are recorded to identify patients at risk, as the dose measures and tumour volume cannot be considered correlated.en
dc.language.isoenen
dc.titleBreast dose in young women treated for Hodgkin Lymphoma between 2007 and 2018: a single institutional studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversity of Manchesteren
dc.identifier.journalInternational Journal of Radiation Oncology Biology Physicsen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record